Gordon Philipp Otto

Gordon Philipp Otto has a diverse and extensive work experience in the pharmaceutical industry.

In their most recent position at MorphoSys, they serve as the Head of Global Clinical Development, a role they have held since 2022.

Prior to their current role, they worked at Pieris Pharmaceuticals as the Head of Clinical Development Oncology. In this position, they provided strategic leadership and operational oversight for clinical development, clinical operations, pharmacovigilance, and regulatory affairs. Their responsibilities included managing an oncology pipeline, reporting directly to the CEO, and collaborating with board members to align with corporate objectives. Gordon Philipp held this role from July 2022 to November 2022.

Before joining Pieris Pharmaceuticals, Gordon worked at Merck KGaA, Darmstadt, Germany, for several years. Gordon Philipp served as a Senior Medical Director from June 2021 to July 2022, and previously as a Medical Director from June 2019 to June 2021. In these roles, they focused on submission activities in various lead regions and indication extensions in the field of NSCLC, GI, and CRC. Gordon Philipp worked on projects such as Tepotinib and Tepmetko, collaborating with regulatory authorities including PMDA, FDA, and EMA.

Gordon also gained experience at Sandoz, where they served as the Global Clinical Development Manager from December 2016 to May 2019. In this position, they were responsible for pivotal trials in an oncology biosimilar program and preparation of submission dossiers for health authorities such as EMA and FDA.

Throughout their career, Gordon has held various positions in medical affairs at companies such as Shire, Baxalta, and Baxter International Inc. Gordon Philipp also worked as a physician at the Center for Sepsis Control and Care and the Department of Anesthesiology and Intensive Care Medicine at Jena University Hospital.

Overall, Gordon Philipp Otto has a strong background in clinical development, medical affairs, and regulatory affairs in the pharmaceutical industry.

Gordon Philipp Otto's education history is as follows:

- From 2019 to 2020, they attended Harvard University, where they studied prescription drug regulation, cost, and access in a course called "1962USRx: Prescription Drug Regulation, Cost, and Access: Current Controversies in Context."

- In 2018, they participated in the honor track program at Harvard Medical School, focusing on "HSPH-HMS214x: Fundamentals of Clinical Trials."

- From 2017 to 2018, they studied readings in global health at Harvard T.H. Chan School of Public Health.

- Gordon Philipp completed a Master of Health Business Administration (MHBA) degree at FAU Erlangen-Nürnberg from 2015 to 2017.

- Gordon earned a Doctorate in Molecular Medicine (Dr. rer. nat.) from Friedrich Schiller University Jena between 2013 and 2015.

- Gordon Philipp obtained a Master of Science (MSc) degree in Molecular Medicine from Friedrich Schiller University Jena from 2009 to 2011.

- Gordon earned a medical degree (Dr. med.) from Friedrich Schiller University Jena from 2004 to 2009.

- Their undergraduate studies in medicine included a Grundstudium at Justus Liebig University Giessen from 2002 to 2004.

- Although the specific time frame is not provided, they hold a Doctor of Medicine (MD) degree from the University of Galway and The Hebrew University of Jerusalem.

- Additionally, Gordon has obtained several certifications, including a Master of Health Business Administration (MHBA), a Doctorate in Molecular Medicine (Dr. rer. nat.), a certification in good clinical practice (GCP), a Master of Science in Molecular Medicine, and a Doctorate in Medicine (Dr. med.). Gordon Philipp also possesses a medical license.

It is important to note that the obtained month and institution for the additional certifications are not provided.